1-15 of 15
Randeep Sangha
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Zelenirstat Nmt Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma and Acute Myelogenous Leukemia: Mechanistic Insights and Clinical Outcomes

Randeep Sangha, John Kuruvilla, Laurie H. Sehn, Michael Weickert, Erwan Beauchamp, Jay M. Gamma, Naveen Pemmaraju, Gautam Borthakur, Luc G. Berthiaume, John R. Mackey
Journal: Blood
Blood (2024) 144 (Supplement 1): 5791.
https://doi.org/10.1182/blood-2024-208480
Published: 2024
Journal Articles

A First-in-Human, Open-Label, Phase I Dose Escalation Trial of Daily Oral Nmt Inhibitor Zelenirstat in Patients with Relapsed/Refractory B-Cell Lymphomas and Advanced Solid Tumors

Randeep Sangha, Rahima Jamal, Jennifer Spratlin, John Kuruvilla, Laurie H. Sehn, Michael Weickert, Luc Berthiaume, John Robert Mackey
Journal: Blood
Blood (2023) 142 (Supplement 1): 6241.
https://doi.org/10.1182/blood-2023-190058
Published: 2023
Journal Articles

A First in Class, Open-Label, First-in-Human, Phase I Trial of Daily Oral Pclx-001

Randeep Sangha, Laurie H. Sehn, Rahima Jamal, Jennifer Spratlin, John Kuruvilla, Michael J. Weickert, Luc G. Berthiaume, John R. Mackey
Journal: Blood
Blood (2022) 140 (Supplement 1): 12057–12058.
https://doi.org/10.1182/blood-2022-168140
Published: 2022
Journal Articles

An Open-Label, First-in-Human, Phase I Trial of Daily Pclx-001

Randeep Sangha, John R. Mackey, Laurie H. Sehn, John Kuruvilla, Michael J. Weickert, Luc G. Berthiaume
Journal: Blood
Blood (2021) 138 (Supplement 1): 1364.
https://doi.org/10.1182/blood-2021-153613
Published: 2021
Journal Articles

Nonclinical Efficacy and Toxicity and Selection of a Safe Clinical Starting Dose for an NMT Inhibitor in Development for Hematological Malignancies

Michael J. Weickert, PhD, John Dillberger, DVM, PhD, Caren Brown, Francis Phaneuf, John R. Mackey, MD, Randeep Sangha, MD, Luc G. Berthiaume, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-141910
Published: 2020
Journal Articles

Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma

Loretta J. Nastoupil, MD, Fontanet Bijou, MD, Vincent Ribrag, MD, Julio C. Chavez, MD, Thomas E. Witzig, MD, David J. Andorsky, MD, Leonard M. Klein, MD, Daniel Greenwald, MD, Armando Santoro, MD, Paolo Corradini, MD, Ian W. Flinn, MD PhD, Randeep Sangha, MD, Vaishalee P. Kenkre, MD, Shailaja Uttamsingh, PhD, Patrick R. Hagner, PhD, Anita K. Gandhi, PhD, Tianlei Chen, PhD, Kristen Hege, MD, Michael Pourdehnad, MD, John Kuruvilla, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1602.
https://doi.org/10.1182/blood-2018-99-114409
Published: 2018
Journal Articles

CC-122 DLBCL-001: Phase Ib Study of CC-122 Plus Rituximab in Patients with Chemo-Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Vincent Ribrag, Julio C. Chavez, MD, Umberto Vitolo, MD, Jason B. Kaplan, MD, Jason C. Chandler, MD, Armando Santoro, MD, Paolo Corradini, MD, Ian W. Flinn, MD PhD, Loretta Nastoupil, MD, Philippe A. Cassier, MD, Randeep Sangha, MD, Vaishalee P. Kenkre, MD, Ranjana H. Advani, MD, Iris Isufi, MD, Thomas E Witzig, MD, Michael Petrarca, PhD, Patrick R. Hagner, PhD, Anita K. Gandhi, PhD, Xiaoling Wu, PhD, Kristen Hege, MD, Michael Pourdehnad, MD, John Kuruvilla, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1551.
https://doi.org/10.1182/blood.V130.Suppl_1.1551.1551
Published: 2017
Journal Articles

Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study

Robert E Marcus, Andrew J Davies, FRCP PhD, Kiyoshi Ando, Wolfram Klapper, MD, Stephen Opat, MD, Carolyn J Owen, Elizabeth H Phillips, Randeep Sangha, Rudolf Schlag, John F Seymour, William Townsend, Marek Trněný, Michael K Wenger, Günter Fingerle-Rowson, Kaspar Rufibach, Tom Moore, Michael Herold, Wolfgang Hiddemann, MD
Journal: Blood
Blood (2016) 128 (22): 6.
https://doi.org/10.1182/blood.V128.22.6.6
Published: 2016
Journal Articles

A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001

Vincent Ribrag, MD, Julio C. Chavez, MD, Jason B Kaplan, MD, Umberto Vitolo, MD, Jason C. Chandler, MD, Armando Santoro, MD, Paolo Corradini, MD, Philippe Cassier, MD, Ian W. Flinn, MD PhD, Ranjana Advani, MD, Randeep Sangha, Iris Isufi, MD, Vaishalee P. Kenkre, MD, Patrick R. Hagner, Torsten Trowe, PhD, Anita K. Gandhi, PhD, Xiaoling Wu, PhD, Kristen Hege, MD, Michael Pourdehnad, John Kuruvilla, MD
Journal: Blood
Blood (2016) 128 (22): 1849.
https://doi.org/10.1182/blood.V128.22.1849.1849
Published: 2016
Journal Articles

Aggressive Non-Hodgkin Lymphoma: Predictive Value Of Sarcopenia and Skeletal Muscle Density On Prognosis With Rituximab Containing Therapy

Michael P Chu, MD, Jessica Lieffers, Andrew R Belch, MD, Neil Chua, MD, FRCPC, Amelie Fontaine, MD, Randeep Sangha, A. Robert Turner, MD, FRCPC, Sunita Ghosh, PhD, Michael Sawyer, MD
Journal: Blood
Blood (2013) 122 (21): 3023.
https://doi.org/10.1182/blood.V122.21.3023.3023
Published: 2013
Journal Articles

Indolent Non-Hodgkin Lymphoma: Skeletal Muscle Density Predicts Overall Survival With Rituximab Based Chemotherapy

Michael P Chu, MD, Jessica Lieffers, Andrew R Belch, MD, Neil Chua, MD, FRCPC, Amelie Fontaine, MD, Randeep Sangha, A. Robert Turner, MD, Sunita Ghosh, PhD, Michael Sawyer, MD
Journal: Blood
Blood (2013) 122 (21): 5078.
https://doi.org/10.1182/blood.V122.21.5078.5078
Published: 2013
Journal Articles

Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Maria Corinna Palanca-Wessels, M.D., Ph.D., Gilles Andre Salles, MD, PhD, Myron S. Czuczman, MD, Sarit E. Assouline, MD, Ian W. Flinn, MD, PhD, Laurie H. Sehn, MD, Manish Patel, MD, Randeep Sangha, Herve Tilly, MD, Ranjana Advani, MD, Olivier Casasnovas, MD, Oliver W. Press, MD, PhD, Sreeni Yalamanchili, BSPharm, Robert Kahn, Dan Lu, Akiko Chai, MS, Yu-Waye Chu, Franck Morschhauser
Journal: Blood
Blood (2013) 122 (21): 4400.
https://doi.org/10.1182/blood.V122.21.4400.4400
Published: 2013
Journal Articles

Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

Randeep Sangha, Andrew Davies, PhD, Nam H. Dang, MD, PhD, Michinori Ogura, MD, PhD, David A. MacDonald, MD, Angela Volkert, Revathi Ananthakrishnan, Kenneth Luu, Joseph P. Boni, PhD, Erik Vandendries, MD, Yeow-Tee YT Goh, MD
Journal: Blood
Blood (2013) 122 (21): 1821.
https://doi.org/10.1182/blood.V122.21.1821.1821
Published: 2013
Journal Articles

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Maria Corinna Palanca-Wessels, M.D., Ph.D., Ian W. Flinn, MD, PhD, Laurie H. Sehn, MD, MPH, Manish Patel, MD, Randeep Sangha, MD, Myron S. Czuczman, MD, Gilles Andre Salles, MD, PhD, Franck Morschhauser, MD, Ranjana Advani, MD, Oliver W. Press, MD, PhD, William Ho, MD, PhD, Robert Kahn, Dan Lu, Zheng Su, Yu-Waye Chu, Sarit E. Assouline, MD
Journal: Blood
Blood (2012) 120 (21): 56.
https://doi.org/10.1182/blood.V120.21.56.56
Published: 2012
Journal Articles

An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,

Michinori Ogura, Toshiki Uchida, David A MacDonald, Kiyohiko Hatake, Andrew Davies, Randeep Sangha, Michael Crump, MD, FRCPC, Catherine Thieblemont, MD, Taro Ishibashi, Steven Hua, Luisa Paccagnella, Erik R Vandendries, MD, PhD, Yukio Kobayashi, Kensei Tobinai, MD
Journal: Blood
Blood (2011) 118 (21): 3715.
https://doi.org/10.1182/blood.V118.21.3715.3715
Published: 2011